Search Results

The global artificial intelligence in genomics market size was evaluated at US$ 560 million in 2023 and is expected to attain around US$ 16,431.16 million by 2033, growing at a CAGR of 40.2% from 2024 to 2033.

Prenosis, Inc., an artificial intelligence company enabling precision medicine in acute care, today announced the U.S. Food and Drug Administration (FDA) has granted marketing authorization for the Sepsis ImmunoScore™ using the De Novo pathway.

Intelligent Bio Solutions Inc. today announced that on March 8, 2024, it entered into securities purchase agreements with several healthcare-focused institutional and accredited investors to issue, in a private placement priced at-the-market under Nasdaq rules, 2,223,333 shares of common stock.

The overall survival edge over J&J’s Darzalex will help GSK strengthen its case as it plots the market comeback of Blenrep, which was pulled after a failed confirmatory study.

Biospecimen Market To Exceed $13.5 Billion USD By 2032

Intelligent Bio Solutions Inc. announced the closing of its previously announced private placement priced at-the-market under Nasdaq rules of 2,223,333 shares of common stock, Series H-1 warrants to purchase up to an aggregate of 2,223,333 shares of common stock and Series H-2 warrants to purchase up to an aggregate of 2,223,333 shares of common stock, at a combined purchase price of $4.55 per share of common stock and associated Series H-1 warrants and Series H-2 warrants.

The global artificial intelligence (AI) in life sciences market size was estimated at USD 1,560 million in 2022 and is projected to soar USD 9,800 million in 2032, with a double digit CAGR of 20.21% from 2023 to 2032.